Back to search results

Research Officer

Swansea University - Swansea University Medical School

Location: Swansea
Salary: £35,326 to £40,927 per annum together with USS pension benefits. Grade 8
Hours: Full Time
Contract Type: Fixed-Term/Contract
Placed On: 16th September 2021
Closes: 17th October 2021
Job Ref: AC04780

Contract Type: Fixed Term until 30th September 2024. Full-time.

Location: Swansea University Medical School, ILS1, Singleton Campus

Main Purpose of Post

We are seeking a highly talented and enthusiastic post-doctoral research scientist to join the newly formed T-cell leukaemia research group, working on an exciting new project titled “Drug Repurposing for Paediatric T-cell Acute Lymphoblastic Leukaemia Therapy”. The project is led by Dr Nick Jones (Swansea University Medical School) and is funded by Children’s Cancer and Leukaemia Group and the Little Princess Trust.

T-cell acute lymphoblastic leukaemia (T-ALL) is a malignancy affecting T-cells and accounts for 10-15% of the total ALL group. T-ALL is an aggressive malignancy that sees around 20-50% of patients eventually relapse after treatment, with poor survival rates among relapsing patients. Additionally, current toxic chemotherapeutic treatments are poorly tolerated by the body and frequently elicit severe side effects in paediatric patients. Combinational therapy could decrease the chemotherapeutic dose administered, therefore reducing the toxic side effects in paediatric patients. This project will characterise how metabolic perturbations in T-ALL differ by mutation status at baseline, and then investigate the suitability of metabolism targeted drugs as either a monotherapy or combinational therapy with common T-ALL treatments. This will involve collaboration with researchers at the University of Bristol (Dr Allison Blair), UCL (Dr Marc Mansour) and Rutgers University (Dr Daniel Herranz).

Applicants should have a PhD degree in a biomedical science subject and relevant laboratory experience. Laboratory experience must include metabolomic analysis (extracellular flux and stable isotope tracer analysis) and gene manipulation (interfering RNA or CRISPR). In addition, you must experience in the conduct, interpretation and reporting of qualitative and quantitative research. Evidence of excellent organisational skills, with an appreciation of management of clinical samples (and corresponding data) is essential. Further experience working with suspension cells and oncometabolism is of further benefit.

The role provides an exciting opportunity to join Swansea University Medical School, one of the UK’s leading Medical Schools. Swansea University Medical School provides an interdisciplinary approach, educating and training the next generation of doctors, life scientists, and health professionals. It collaborates with the NHS, business and the third sector in a spirit of open innovation and has established itself as a world-class place to learn, research and innovate.  The Medical School ranks 1st in the UK for research environment and 2nd for overall research quality (REF2014-2021) and 3rd for Medicine (The Times and Sunday Times Good University Guide 2021).

To apply

To apply for the post please click on the link: Post Doctoral Research Officer (

Applicants are asked to provide a completed online application providing evidence against the essential criteria in the recruitment documentation. Applicants should also attach to the application the following documents:

  • Curriculum Vitae;
  • Publication list;
  • Statement detailing your research to date

Informal enquiries are welcome and should be directed to Dr Nick Jones (

We value your feedback on the quality of our adverts. If you have a comment to make about the overall quality of this advert, or its categorisation then please send us your feedback
Advert information

Type / Role:

Subject Area(s):


Job tools
More jobs from Swansea University

Show all jobs for this employer …

More jobs like this
Join in and follow us

Browser Upgrade Recommended has been optimised for the latest browsers.

For the best user experience, we recommend viewing on one of the following:

Google Chrome Firefox Microsoft Edge